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Unconjugated Bilirubin exerts Pro-
Apoptotic Effect on Platelets via 
p38-MAPK activation
Somanathapura K. NaveenKumar1, Ram M. Thushara1, Mahalingam S. Sundaram1, 
Mahadevappa Hemshekhar1,2, Manoj Paul1, Chinnasamy Thirunavukkarasu3,  Basappa4, 
Ganesh Nagaraju5, Sathees C. Raghavan5, Kesturu S. Girish1,6, Kempaiah Kemparaju1 & 
Kanchugarakoppal S. Rangappa7
Thrombocytopenia is one of the most frequently observed secondary complications in many 
pathological conditions including liver diseases, where hyperbilirubinemia is very common. The 
present study sought to find the cause of thrombocytopenia in unconjugated hyperbilirubinemic 
conditions. Unconjugated bilirubin (UCB), an end-product of heme catabolism, is known to have 
pro-oxidative and cytotoxic effects at high serum concentration. We investigated the molecular 
mechanism underlying the pro-apoptotic effect of UCB on human platelets in vitro, and followed it 
up with studies in phenylhydrazine-induced hyperbilirubinemic rat model and hyperbilirubinemic 
human subjects. UCB is indeed found to significantly induce platelet apoptotic events including 
elevated endogenous reactive oxygen species generation, mitochondrial membrane depolarization, 
increased intracellular calcium levels, cardiolipin peroxidation and phosphatidylserine externalization 
(p < 0.001) as evident by FACS analysis. The immunoblots show the elevated levels of cytosolic 
cytochrome c and caspase activation in UCB-treated platelets. Further, UCB is found to induce 
mitochondrial ROS generation leading to p38 activation, followed by downstream activation of p53, 
ultimately resulting in altered expression of Bcl-2 and Bax proteins as evident from immunoblotting. 
All these parameters conclude that elevated unconjugated bilirubin causes thrombocytopenia by 
stimulating platelet apoptosis via mitochondrial ROS-induced p38 and p53 activation.
Unconjugated hyperbilirubinemia is an incidental verdict on routine laboratory tests in most liver diseases 
including chronic liver disease, haemolytic jaundice, Gilbert’s syndrome and Crigler-Najjar syndrome1–3. 
Liver disorders quite often present haematological aberrations particularly thrombocytopenia (low plate-
let count). As high as 58% of liver disease patients are observed to have thrombocytopenia correlating 
increased concentration of bilirubin4. Consequently, the extent of thrombocytopenia is found to serve 
as an effective prognostic marker for liver diseases4,5. Thrombocytopenia not only leads to increased 
bleeding and haemorrhage, but also is an impediment to invasive procedures including diagnosis and 
therapeutic regimen. One of the reasons behind thrombocytopenia might be rapid destruction or clear-
ance of platelets in the peripheral circulation. This is supported by various reports lately including our 
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own, that demonstrate the intensely sensitive and fragile nature of platelets, as well as their tendency to 
undergo apoptosis in response to a wide array of intrinsic and extrinsic stimuli6. The anuclear platelets 
possess the necessary cellular machinery to undergo apoptosis like any other nucleated cell, with the 
exception of nuclear apoptotic events. The intrinsic apoptotic pathway is more commonly demonstrated 
in platelets, which transpires via mitochondrial dysfunction in response to stress and is presented with 
augmented levels of reactive oxygen species (ROS), mitochondrial membrane potential (Δ Ψ m) depolar-
ization, intracellular calcium ions (Ca2+), cytosolic cytochrome c (cyt. c), caspases −9 and −3 activities, 
and phosphatidylserine (PS) scrambling7,8.
Although the link between thrombocytopenia and liver diseases is quite apparent, at present the 
scientific community does not acknowledge liver disease as a probable cause of thrombocytopenia. 
Therefore, the present study sought to delve into the mechanism behind this phenomenon. One com-
mon hallmark in the liver diseases, including haemolytic jaundice, Gilbert’s syndrome and Crigler-Najjar 
syndrome, is elevated level of serum unconjugated bilirubin i.e. hyperbilirubinemia. Unconjugated bil-
irubin (UCB) is the reduced product of biliverdin and is an end-product of heme (Fe-protoporphyrin 
IX) catabolism. It is made in the Kupffer (hepatic) cells and in monocytic macrophages of bone marrow 
and spleen, which is then released into plasma9. UCB behaves as a physiological antioxidant in human 
extracellular fluids10,11. However, it is also demonstrated that bilirubin in the presence of the transition 
metal ion Cu (II) induces DNA strand cleavage via generation of ROS, particularly hydroxyl radical12. 
Hence, UCB acts as an antioxidant at normal physiological concentration and as a pro-oxidant at higher 
concentration, where it may reach up to 300 μ M11. High concentration of UCB is linked to cell cytotoxic-
ity and neurological dysfunctions13. On the other hand, there are studies that have reported the platelets 
undergo apoptosis in response to oxidative stress14–16. Accordingly, it is hypothesized that elevated levels 
of UCB during a disease condition might exert oxidative stress on platelets and thus trigger the process 
of apoptosis. Therefore, the present study demonstrates the pro-apoptotic potential of UCB on human 
platelets as an attempt to correlate hyperbilirubinemia and thrombocytopenia, and also explores the 
underlying molecular signalling pathway. We also report the observed incidences of thrombocytopenia 
in hyperbilirubinemia patients, as well as activated apoptotic markers in their platelets. Taken together, 
we demonstrate the clinical significance of UCB in depleting platelet count during hyperbilirubinemic 
conditions, which demands a collective treatment strategy considering the risks associated with throm-
bocytopenia during liver diseases.
Results
UCB induces oxidative stress and apoptosis in platelets. To investigate whether UCB affects 
platelet function and life span, we examined the oxidative stress and apoptotic markers of platelets in 
presence or absence of UCB. UCB-treated platelets were assessed for oxidative stress parameters like 
endogenous ROS generation, intracellular calcium content and Δ Ψ m depolarization. FACS analysis of 
UCB-treated platelets showed concentration-dependent increase in ROS generation measured using 
DCF fluorescence (Fig. 1A). To rule out the interference of UCB fluorescence at the similar excitation 
and emission range of DCF, UCB -treated platelets were monitored for fluorescence without adding DCF 
dye. We found no observable fluorescence in UCB-treated platelets suggesting that UCB do not inter-
fere with DCF fluorescence (Supplementary Figure 1). It is established that impaired functions of ETC 
complex is the primary event leading to mitochondrial ROS production17,18. Therefore, effect of UCB 
on ETC complex was evaluated. UCB significantly inhibited complex II and complex IV activities in a 
concentration-dependent manner (Fig.  1B). Additionally, ROS generation induced by disturbances in 
ETC was confirmed using Mito-TEMPO, a mitochondria targeted anti-oxidant. It significantly abolished 
UCB-induced endogenous ROS generation, indicating that mitochondria are the primary source of ROS 
in unconjugated hyperbilirubinemia (Fig.  1C). Fluorometric analysis of UCB-treated platelets showed 
concentration-dependent increase in intracellular calcium levels (Fig. 1D) together with decreased Δ Ψ m 
(Fig. 1E). As discussed earlier, to exclude the interference of UCB with JC1 fluorescence, (used to detect 
Δ Ψ m) unstained UCB-treated platelets were monitored for fluorescence and we observed no change 
suggesting UCB do not interfere with JC1 fluorescence (Supplementary Figure 2). Altered mitochon-
drial dysfunction and calcium homeostasis are marked with peroxidation of cardiolipin, release of cyt. 
c into cytosol via mPTP, downstream caspase activation and PS externalization. Accordingly, UCB trig-
gered cardiolipin peroxidation (Fig. 2A) and mPTP formation as determined by calcein-CoCl2 quench-
ing assay (Fig.  2B). Further, downstream apoptotic events like cyt. c release, activation of caspase-9 
and caspase-3 were evaluated using immunoblotting (Fig. 2C). It is demonstrated that during apoptosis 
cellular proteins can be phosphorylated through the activation of protein kinases and then exposed to 
caspase cleavage19. Consistent with this notion, we observed increased phosphorylated protein content in 
UCB-treated platelets using immunoblot (Fig. 2D) and flow cytometric analysis endorsed that there was 
concentration-dependent PS externalization in UCB-treated platelets (Fig. 2E). In all the assays, vehicle 
control (DMSO) was found to be non-toxic to platelets and did not induce either apoptosis or oxidative 
stress to platelets.
In order to assess the toxicity of UCB towards platelets, UCB-treated platelets were assessed for their 
viability. There was a significant decrease in G6PDH activity (Fig.  3A), increase in GGT activity of 
platelets (Fig. 3B) suggesting that platelets were in oxidative stress due to UCB treatment. The increased 
levels of lysosomal alkalinization, LDH release and MTT assay in platelets confirm the cytotoxic effect 
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of UCB on platelets and a significant reduction in the viability of UCB-treated platelets (Fig.  3C–E). 
Further, we evaluated the macrophage-mediated clearance of UCB treated platelets by FACS analysis. 
We observed a significant increase in calcein fluorescence in macrophages incubated with UCB-treated 
platelets (Fig. 3F) suggesting that platelets undergo apoptosis upon UCB treatment.
Our next question was to determine whether UCB treatment activates platelets. To verify the activa-
tion of platelets, platelet aggregation and platelet adhesion assays were performed. UCB did not induce 
platelet aggregation by itself; however, it inhibited collagen-induced platelet aggregation in washed plate-
lets at a lower dose (Supplementary Figure 3A–C). In addition, UCB altered the adhesive property of 
Figure 1. UCB induced oxidative stress and mitochondrial stress in human platelets. (A) Flow 
cytometric analysis of ROS in UCB treated platelets, (B) Effect of UCB on components of mitochondrial 
electron transport chain, (C) Effect of Mito-TEMPO on UCB induced ROS generation. (D) Flourometric 
analysis of intracellular calcium level and (E) Flow cytometric analysis of mitochondrial membrane 
potential. Values are presented as mean ± SEM (n = 5) and expressed as percentage increase in (C) DCF and 
(D) Fura fluorescence. */# p< 0.05, **p < 0.01, ***/### p< 0.001; *significant compared to control platelets;  
#significant compared to UCB alone treated platelets.
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washed platelets towards collagen (Supplementary Figure 3D). Together, these findings attest a prior 
knowledge that UCB affects platelet function and primes them into apoptosis and not their activation.
UCB-induces platelet apoptosis through p38-mediated mitochondrial dysfunction. Apoptosis 
in UCB-treated platelets was so profound that nearly half of the treated population had undergone death 
as conferred by PS externalization and MTT assay. Therefore, we found it interesting to delineate the 
molecular mechanism of UCB-induced platelet apoptosis; hence phosphorylation of proteins involved 
in apoptosis signalling cascade was evaluated using immunoblotting. It is well established in plate-
lets that MAP kinases play a significant role during mitochondrial dysfunction-mediated apoptosis20. 
Interestingly, there was increased phosphorylation of p38 (Thy180/Tyr182) as well as phosphorylation 
of p53 (Ser15) in platelets treated with UCB (Fig. 4A). Alongside, there was significant up-regulation of 
pro-apoptotic Bcl-2 family protein Bax, together with down-regulation of pro-survival proteins Bcl-2, 
phospho Bad, demonstrating that mitochondrial dysfunction was mediated by p53 (Fig.  4B). Further, 
there was an increased localization of Bax and phospho p53 in mitochondrial fraction and cyt. c in 
cytosolic fraction of platelets treated with UCB suggesting that p53 has a definite role in mitochondrial 
dysfunction (Fig. 4C).
In order to confirm the involvement of MAPK kinases in UCB-triggered platelet apoptosis, spe-
cific inhibitors of MAPK pathway were used. Under physiological conditions, albumin binds to UCB 
Figure 2. UCB induced mitochondrial dysfunction and apoptosis in human platelets. (A) Flow 
cytometric analysis of cardiolipin peroxidation in UCB treated platelets. (B) UCB induced mPTP formation 
(C) Immunoblots showing expression of cytochrome c, active caspase-9 and caspase-3. (D) Effect of UCB 
on protein phosphorylation. Membrane was cut based on the molecular weight, probed with antibody of 
interest and band of interest with molecular weight is indicated with an arrow. (E) Flow cytometric analysis 
of PS externalization in UCB treated platelets. Values are presented as mean ± SEM (n = 5), expressed 
as percentage decrease in (B) calcein. *p < 0.05, **p < 0.01, ***p < 0.001; significant compared to control 
platelets.
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in circulation and hence inhibits its action towards the cells that are in close proximity. As expected, 
the immunoblotting data showed the decreased phosphorylation of p38 and p53 in UCB-BSA 
conjugate-treated platelets (Fig.  5A). Additionally, Mito-TEMPO (mitochondrial ROS scavenger) also 
inhibited p38 and p53 phosphorylation, indicating that their activation was due to mitochondrial ROS 
production (Fig. 5A). To explore whether p53 was being activated by p38, SB203580 a specific p38 inhib-
itor was used. Phosphorylation of p53 was inhibited by SB203580 suggesting that the phosphorylation 
was mediated by p38 activation (Fig. 5B). Further to confirm that UCB mediates apoptosis in platelets 
through p38 MAPK, the downstream apoptotic markers like Bcl-2, Bax and caspase-3 expression were 
evaluated both in presence and absence of SB203580 (Fig.  5B). Interestingly, SB203580 restored the 
altered levels of Bcl-2, Bax and caspase-3 in UCB-treated platelets as compared to untreated platelets. 
Furthermore, Pifithrin-μ , a specific blocker of p53- Bcl-xL/Bcl-2 interaction, inhibited cyt. c release and 
caspase-3 activation, and increased PS levels in UCB-treated platelets as compared to untreated platelets 
(Fig. 5C), indicating that UCB triggers apoptosis in platelets via p53-mediated activation of Bcl-2 family 
proteins and caspases. The specific caspase inhibitor z-DEVD-fmk, also restored the elevated PS levels 
establishing further that UCB- induced platelet apoptosis is caspase dependent (Fig. 5D,E).
Figure 3. UCB induced cytotoxicity in human platelets. UCB induced oxidative stress and lysosomal 
alkalinisation as assessed by (A) G6PDH activity (B) GGT activity and (C) Lysosomal stability. Cytotoxic 
properties of UCB as determined by (D) LDH leakage (E) MTT cell viability assay and (F) Flow cytometric 
analysis of macrophages mediated engulfment of calcein-labeled control and UCB (100 μ M) treated platelets. 
Values are presented as mean ± SEM (n = 5), expressed as percentage decrease in (C) LysoSensor Green 
DND-189 fluorescence. *p < 0.05, **p < 0.01, ***p < 0.001; significant compared to control platelets.
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UCB alters platelet apoptosis markers in rat model. Since, it was clear from the previous set of 
results that UCB induces platelet apoptosis, it was ideal to ascertain the effects of UCB in vivo. Therefore, 
phenylhydrazine (PHZ)-induced hyperbilirubinemic animals were initially evaluated for platelet count. 
PHZ administration effectively induces haemolytic hyperbilirubinemia in the rats, which is close enough 
to human haemolytic jaundice with elevated UCB levels21. We observed a significant decrease in the pop-
ulation of circulating platelets (Fig. 6A) with elevated serum UCB levels (Fig. 6B). The platelet apoptotic 
Figure 4. Differential expression of signalling proteins and mitochondrial accumulation of 
phosphorylated p53 in UCB treated platelets. (A) Immunoblots showing expression of phospho p38 and 
phospho p53 in UCB treated platelets. (B) Effect of UCB on cytosolic Bcl-2 family proteins expression 
(Bcl-2, tBid, phospho BAD and BAD) in platelets. (C) Expression of, Bax, cyt. C and phospho p53 in both 
mitochondria and cytosolic fractions of UCB treated platelets. COX-IV indicates cytochrome c oxidase 
subunit-IV used as mitochondrial loading control and β -tubulin as loading control for cytosolic fractions. 
Membrane was cut based on the molecular weight, probed with antibody of interest and band of interest 
with molecular weight is indicated with an arrow.
Figure 5. Inhibition of UCB mediated platelet apoptosis by different inhibitors. Immunoblots showing 
the effect of (A) BSA and Mito-TEMPO, a mitochondrial ROS quencher (B) SB203580 (specific p38 
inhibitor) and (C) Pifithrin-μ (specific p53 inhibitor) on UCB induced platelet apoptosis. Effect of  
(D) Pifithrin-μ and (E) z-DEVD-fmk (specific caspase-3 inhibitor) on UCB induced PS externalization. 
Membrane was cut based on the molecular weight, probed with antibody of interest and band of interest 
with molecular weight is indicated with an arrow. *p < 0.05, ***/### p< 0.001; *significant compared to 
control platelets; #significant compared to UCB alone treated platelets.
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markers like endogenously generated ROS, intracellular calcium, Δ Ψ m, cardiolipin peroxidation and PS 
externalization were also altered in PHZ-induced hyperbilirubinemic rats in a similar pattern as the in 
vitro results (Fig. 6C). In the previous set of experiments, activation of p38 and p53 were shown to be 
critical in UCB-mediated mitochondrial damage, hence platelets from the hyperbilirubinemic rats were 
evaluated for the same. Increased phosphorylation of p38 and p53 along with decreased Bcl-2 levels and 
increased levels of Bax, cyt. c and caspase-3 were clearly evident from respective immunoblots suggesting 
that the decreased platelet count was due to hyperbilirubinemia (Fig. 6D). To exclude the fact that PHZ 
itself interferes with altered platelet properties, platelets were treated with PHZ in vitro. As the results 
demonstrate, the alterations in ROS content, intracellular calcium levels, Δ Ψ m, cardiolipin peroxida-
tion, mPTP formation, PS externalization and LDH activity were found to be negligible (Supplementary 
Figure 4). In addition, altered serum cytokine levels were also observed in PHZ-induced hyperbiliru-
binemic rats compared to control (Fig.  7A). A significant difference in macroscopic and microscopic 
structure of both liver (Fig. 7B) and spleen (Fig. 7C) was observed in PHZ-induced hyperbilirubinemic 
rats compared to saline control.
UCB-triggers platelet apoptosis in hyperbilirubinemic human subjects. Further, to validate 
the link between thrombocytopenia and hyperbilirubinemia, hyperbilirubinemic (HB) patients were 
recruited and the correlation between indirect bilirubin level and platelet count was determined. As 
hypothesized, there was a significant decrease in the number of circulating platelets (Fig. 8A) along with 
elevated UCB levels (Fig. 8B) in HB subjects compared to HS. Therefore, platelet apoptotic markers and 
intracellular signalling events were evaluated in HS and HB subjects. There was significant alteration 
in platelet apoptotic markers like endogenous generation of ROS, intracellular calcium, Δ Ψ m, cardi-
olipin peroxidation, mPTP formation and PS externalization (Fig.  8C). The obtained results were fur-
ther backed up by demonstrating the decreased lysosomal acidity (Fig. 8D) and increased GGT activity 
(Fig. 8E). Moreover, the phosphorylated forms of p38 and p53 were also elevated significantly together 
with apoptotic markers like decreased Bcl-2 and increased levels of Bax, cyt. c and caspase-3 (Fig. 8F). 
The obtained results manifestly demonstrate the subliminal path of UCB priming circulating platelets 
into their deaths via an intricate cellular mechanism (Fig. 8G).
Discussion
The current study for the first time, probed the cause of thrombocytopenia in unconjugated hyperbili-
rubinemia. Unconjugated hyperbilirubinemia is a common characteristic feature in liver diseases such 
as haemolytic jaundice, Gilbert’s syndrome and Crigler-Najjar syndrome1–3. Thereby, it is conjectured 
that there might be a link between hyperbilirubinemia and thrombocytopenia. Of note, thrombocy-
topenia is frequently observed in 58% of patients with liver diseases, which correlates with increased 
concentration of bilirubin4. The consequences of thrombocytopenia include increased risk of internal 
Figure 6. Phenylhydrazine induced hyperbilirubinemia in experimental animals. Figure showing 
decreased circulating platelets and increased platelet apoptotic markers during phenylhydrazine (PHZ) 
induced hyperbilirubinemia. Effect of hyperbilirubinemia on (A) Platelet count and (B) Serum direct and 
indirect bilirubin level in control and PHZ treated rats. (C) Elevated apoptotic markers in washed platelets 
obtained from control and PHZ treated rats as assessed by fluorometric assays and presented as percentage 
increase/decrease in fluorescence (ROS, intracellular Ca2+, Δ Ψ m, cardiolipin peroxidation and PS 
externalization). (D) Expression levels of cytosolic apoptotic proteins in washed platelets of control and PHZ 
treated rats. Membrane was cut based on the molecular weight, probed with antibody of interest and band 
of interest with molecular weight is indicated with an arrow. **p < 0.01, ***p < 0.001; significant compared to 
saline control rats.
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and external bleeding, delay in wound healing and coagulation defects. Moreover, it can become a clin-
ically significant predicament in liver disease patients who have to undergo invasive diagnosis/therapy, 
interferon treatment, liver transplantation, cancer chemotherapy and surgery22. Though UCB is a meta-
bolic waste product, it is also shown to be an endogenous antioxidant in mammalian tissues, and makes 
up a greater part of the antioxidant activity in human serum10,11. Bilirubin and biliverdin are potent 
modulators of cell signalling as well23,24. Nevertheless, unconjugated hyperbilirubinemia is associated 
with pathological conditions such as, increased haemolysis or haemolytic jaundice, Gilbert’s syndrome, 
and Crigler-Najjar syndrome3. UCB is also shown to exert cytotoxic and pro-apoptotic effects on neural 
cells and tumour cells25. Therefore, the present study investigated whether UCB affects platelet life span 
to trigger thrombocytopenia in liver diseases associated with elevated UCB levels. The results of the 
present study indicate that UCB induces platelet apoptosis in vitro at the concentration range 0–200 μ M, 
due to the presence of UCB-binding proteins like albumin and other plasma proteins we deliberate our 
data with high concentration of UCB (0–200 μ M). The mitochondrial/intrinsic pathway of apoptosis was 
mainly probed because of its susceptibility to physiological and pathological oxidative stress-inducing 
factors. Bilirubin is reported to be as efficient as anti-oxidants like glutathione and vitamin E in foraging 
hydroxyl radicals. However, elevated serum levels of UCB often exhibit pro-oxidative effect, which might 
be responsible for its anti-microbial properties. In the present study, UCB was found to considerably 
trigger the endogenous generation of ROS in platelets. Previously, few anti-oxidants such as resveratrol, 
sesamol and melatonin were also reported to trigger platelet apoptosis via ROS generation6. High level of 
UCB can lead to kernicterus (brain dysfunction) and studies suggest that oxidative stress is an important 
factor in bilirubin-induced neurotoxicity26. ROS plays a pivotal role in setting off the apoptotic events 
in platelets via the mitochondrial pathway by Δ Ψ m dissipation. Mitochondria perform the function 
of biological switches that decide the fate of the respective cells by supplying the required energy for 
cell survival, and when there are lethal stimuli they trigger cell death27. The current results show that 
UCB significantly stimulates cardiolipin oxidation, Δ Ψ m depolarization, which underscores the noxious 
effect of UCB on mitochondria. Bilirubin was previously reported to be toxic to astrocytes and neurons 
by causing damage to mitochondria and thus, leading to impaired energy metabolism and apoptosis28. 
Figure 7. The serum cytokine levels, morphology and photomicrographs of liver and spleen tissues of 
control and PHZ induced hyperbilirubinemic experimental rats. (A) Altered serum cytokine levels in 
control and PHZ treated rats. Membrane was cut based on the molecular weight, probed with antibody 
of interest and band of interest with molecular weight is indicated with an arrow. GAPDH and rat serum 
albumin (RSA) were used as loading controls. The gel in this figure is cropped and the full length gel is 
presented in supplementary Figure 6. (B) Liver weight, morphology and photomicrographs of liver sections 
(H&E stained) of PHZ induced hyperbilirubinemic experimental rats. Arrow indicates damaged foci with 
large number of inflammatory cells in the sinusoid indicative of congestion as compared to saline control 
rats showing normal foci. (C) Spleen weight, morphology and photomicrographs of H&E stained spleen 
sections of PHZ induced hyperbilirubinemic experimental rats. Arrow indicates damaged spleenic nodule 
and germinal center of white pulp with constricted central artery as compared to saline control rats. 
*p < 0.05; significant compared to control rats.
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Furthermore, oxidative stress can cause perturbations in intracellular Ca2+ homeostasis. At high concen-
trations (> 1 μ M), Ca2+ could inhibit respiration, cause cardiolipin oxidation, mitochondria to undergo 
permeability transition and release pro-apoptotic proteins leading to cell death29,30. Cardiolipin oxida-
tion is a key event in mitochondrial dysfunction as well as in the early stages of the mitochondrial 
apoptotic pathway as it is the primary target of ROS31. Externalization of oxidized cardiolipin from the 
inner mitochondrial membrane to the outer, allows mPTP formation resulting in cyt. c leakage into the 
cytosol32. In the present study UCB was found to bring forth a remarkable increase in intracellular Ca2+ 
concentration and cardiolipin oxidation. Endoplasmic reticulum stress-induced perturbation in Ca2+ 
homeostasis and ROS generation leading to hepatocyte apoptosis has been observed as a pathological 
event in several liver diseases. The transcription factor C/EBP homologous protein, the mitogen activated 
protein kinase c-jun N-terminal kinase (JNK), Bcl-2 family proteins and caspase activation has been 
Figure 8. Effect of hyperbilirubinemia on platelets, platelet apoptotic markers, stress markers and 
expression of apoptotic proteins in human hyperbilirubinemic subjects. Effect of hyperbilirubinemia 
on (A) Platelet count and (B) Serum indirect bilirubin level in HS (n = 21) and HB (n = 35) subjects. 
(C) Hyperbilirubinemia induces platelet apoptosis in HB subjects as assessed by fluorometric assays 
and presented as percentage increase/decrease in fluorescence [ROS, intracellular Ca2+, mitochondrial 
membrane potential, cardiolipin peroxidation, mPTP formation in HS (n = 5) and HB (n = 8) subjects and 
PS externalization]. Effect of hyperbilirubinemia on (D) lysosomal stability as expressed as percent decrease 
in LysoSensor Green DND-189 fluorescence. (E) GGT activity in HS (n = 5) and HB (n = 8) subjects. 
(F) Cytosolic apoptotic protein expression levels in platelets of HS and HB subjects. β -tubulin was used 
as loading control. Membrane was cut based on the molecular weight, probed with antibody of interest 
and band of interest with molecular weight is indicated with an arrow. (G) Schematic representation of 
proposed molecular mechanism of UCB induced platelet apoptosis. Values are presented as mean ± SEM 
and expressed as percentage increase/decrease in DCF, JC-1, fura, NAO and calcein fluorescence. **p < 0.01, 
***p < 0.001; significant compared to HS.
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linked to ER-stress induced apoptosis33,34. UCB was found to decrease the activity of complex II and 
IV of ETC, increase mPTP formation and cytosolic cyt. c. Further, it was also observed to up-regulate 
pro-apoptotic Bcl-2 family protein Bax and tBid, down-regulate Bcl-2, activate caspases-9 and -3 and 
increase protein phosphorylation in a dose-dependent manner in platelets. Activated caspases can cleave 
a wide range of cellular substrates to expose new sites on proteins for phosphorylation19 and hence, 
increased levels of tyrosine-phosphorylated proteins are observed in UCB-treated platelets. Furthermore, 
UCB was capable of provoking PS externalization, an indispensable biochemical feature of an apoptotic 
cell that signals the phagocytic cells, finally leading to cell death. To rule out the possibility of exteri-
orized PS as a consequence of platelet activation, platelet aggregation studies were carried out wherein 
UCB was found to have no influence on platelet aggregation. UCB can easily enter the cells by simple 
passive diffusion and trigger toxicity35. Hence, overall toxic effects of UCB towards platelets were further 
confirmed by the positive results for MTT and LDH assays, decreased G6PDH activity and lysosomal 
stability, and increased GGT activity. G6PDH is involved in the generation of NADPH responsible for 
the recycling of glutathione and thus combating oxidative stress. Decreased platelet G6PDH activity in 
oxidative stress-induced pathologic conditions and in neonatal indirect hyperbilirubinemia has been 
reported36,37. Similarly, GGT is shown to cleave GSH into glutamic acid and cysteinylglycine, result-
ing in GSH depletion; hence, elevated levels of GGT indicate ongoing oxidative stress38. If the platelets 
are undergoing apoptosis, it should be cleared by the reticuloendothelial system through phagocytosis. 
Several studies have demonstrated the phagocytosis of apoptotic platelets using macrophage39–41. In the 
present study, phagocytosis of apoptotic platelets by macrophages was observed and confirms the UCB 
induced platelet apoptosis. Altogether, the findings suggest the platelet pro-apoptotic nature of UCB in 
vitro. The study was further extended to in vivo PHZ-induced hyperbilirubinemia rat model as well as 
hyperbilirubinemic human subjects. Interestingly, in both the cases it was found that there was not only 
a marked decrease in platelet count, but also all the above-mentioned events of mitochondrial apoptotic 
pathway were observed. These findings provide a substantial evidence for the pro-apoptotic effect of 
UCB in vivo.
The next phase of the study aimed to probe the molecular mechanism of UCB-induced platelet 
apoptosis. Various stress stimuli including ROS can activate JNK and p38 MAPK signalling. Platelets 
have also been shown to comprise of key signalling proteins (Bcl family proteins), which regulate 
mitochondria-mediated apoptosis34. Tang et al.42 have also reported the phosphorylation of p38 in 
human platelets by elevated glucose levels, which in turn phosphorylate p53. Both expression of p53 
and its phosphorylation are shown both in mitochondrial and cytosolic platelet fractions43. In addition, 
it is demonstrated that activated p53 induces mitochondrial damage by interacting with Bcl-xL. It was 
studied using pifithrin-μ , a p53-specific inhibitor that inhibits p53 binding affinity towards mitochon-
drial Bcl-xL/ Bcl-2 as well as inhibits p53-mediated mitochondrial dysfunction and apoptosis44. On the 
other hand, it was previously reported that UCB induces oligodendrocyte precursor cell death via JNK 
activation, mitochondrial dysfunction and ROS generation45. In our study, UCB was found to trigger the 
phosphorylation of p38 and p53 in a dose-dependent manner. From the in vitro findings of the study, 
the molecular pathway was worked out as: UCB induces mitochondrial ROS generation, which in turn 
activates p38 and then causes the downstream activation of p53, eventually resulting in up-regulation of 
pro-apoptotic protein Bax and down-regulation of pro-survival proteins Bcl-2 and phospho Bad. Further, 
specific inhibitors of p38 and p53 evidently demonstrate that UCB induces apoptosis in platelets via p38 
and p53 activation. Hence, we clearly demonstrate that activation of p53 is the ultimate key downstream 
event in UCB-driven apoptosis in platelets. In addition, we also reveal that mitochondria are the chief 
resources for ROS production in platelets and are accountable for UCB-induced p38 and p53 activation, 
and platelet toxicity by using Mito-TEMPO. The findings were further confirmed through in vivo rat 
model as well as hyperbilirubinemic human subjects.
The study also demonstrates that UCB induces apoptosis in platelets, but did not activate them as 
evident from platelet aggregation assay. UCB did not affect platelet aggregating properties, however it 
inhibited collagen-induced platelet aggregation in washed platelets at lower doses. Previous studies have 
reported that UCB at lower doses had no effect on platelet aggregation of platelet rich plasma, but 
it did inhibit at higher doses. This justifies that the albumin and some plasma proteins would bind 
UCB through non-covalent interaction, thus nullifying its effect on platelets. Further, the effect of UCB 
on platelet aggregation with collagen was confirmed with the platelet adhesion assay. In which, a sig-
nificant inhibition UCB pre-treated collagen-coated wells and UCB pre-treated WP directly added to 
collagen-coated wells are observed. This might be due to the existence of an interaction between UCB 
and collagen. The results of the present study are contradictory to those presented in earlier studies that 
showed platelets undergoing activation upon exposure to increased levels of UCB in washed platelets46,47. 
This disparity in the results could be attributed to the difference in the protocols and solubility of UCB 
as discussed by Kundur et al.48.
Apoptotic platelets release negatively charged PS-positive plasma membrane vesicles, which are known 
as microparticles (MPs). MPs not only provide surface area for thrombus formation but also stimulate 
coagulation and influence vascular functions due to their pro-inflammatory nature. These events eventu-
ally lead to development of thrombotic disorders, CVDs and arthritis. Therefore, the future perspective of 
the study is to probe the link between hyperbilirubinemia and other pathophysiological conditions, espe-
cially inflammatory diseases. Overall the current study gives a better understanding of a novel approach 
www.nature.com/scientificreports/
1 1Scientific RepoRts | 5:15045 | DOi: 10.1038/srep15045
to deal with thrombocytopenia associated with liver diseases with elevated UCB. Unconjugated hyperbil-
irubinemia should be taken more seriously and not treated as just one of the symptoms of liver diseases. 
Since UCB decreases platelet count by triggering platelet apoptosis via mitochondrial ROS-induced acti-
vation of p38 and p53, platelet protective antioxidants could be used to deal with thrombocytopenia in 
liver diseases. Moreover, the existing medications for liver diseases might themselves stimulate platelet 
apoptosis. Therefore, it is necessary to deal with hyperbilirubinemia and thrombocytopenia in human 
pathologies associated with the conditions of elevated unconjugated bilirubin.
Materials and Methods
Chemicals. All fluorogenic, non-fluorogenic dyes, Histopaque-1077 and standard platelet agonists 
were from Sigma Chemicals, USA. Monoclonal anti-cytochrome c antibody was from Epitomics, USA. 
z-DEVD-fmk, SB203580, ABT-737, Pifithrin-μ , antibodies against caspase-3, caspase-9, Bax, Bcl-2, BAD, 
phospho-BAD (ser136), Bid and tBid were from Santa Cruz Biotechnology, Inc., USA. Phospho-p38 
(Thr180/Tyr182), p38, phospho-p53 (ser15), p53, COX-IV and β -tubulin antibodies were from Cell 
Signalling and Technology, USA. TNF-α , IL-1β and IL-6 antibodies were from Komabiotech, Korea. 
IL-10 and IL-23 antibodies were from Thermo Fisher Scientific, USA. LysoSensor green DND-189 was 
from Molecular probes, USA. Phenylhydrazine hydrochloride (PHZ) was from Fisher Scientific, USA. 
Commercial bilirubin and LDH estimation kits were purchased from Agappe Diagnostics Limited, India.
Preparation of UCB solution. Unconjugated bilirubin (UCB, purity- 99%) used for the study was 
purchased from Sisco Research Laboratories, India. Purity of UCB was again confirmed by RP-HPLC 
which showed 99% pure (Data not shown). UCB was dissolved in dimethyl sulfoxide (DMSO)48, as UCB 
is partially soluble and forms precipitate in 0.02% cetyltrimethylammonium bromide (CTAB) and 0.1 N 
NaOH. Further, UCB solution was centrifuged at 4000 × g to pellet the precipitate and the concentration 
was determined by spectrophotometric method and using bilirubin estimation kit according to the man-
ufacturer’s protocol. We found that there was no change in UCB concentration solubilised in DMSO, but 
there was decreased UCB concentration in CTAB and NaOH solubilised UCB. (Supplementary Figure 5). 
Therefore for the further assays, UCB was dissolved in DMSO to obtain a 10 mM stock solution from 
which the working solutions of 5 mM and 1 mM were prepared in DMSO. The final concentration of 
DMSO was limited to less than 4% in the reaction mixture. The UCB stock/working solutions were pre-
pared in amber tubes and reactions were performed in dark/dim light to avoid photo oxidation of UCB. 
UCB solution was prepared freshly every time within 10 min, before treatment.
Preparation of platelet-rich plasma and washed platelets. Venous blood was drawn from 
healthy volunteers (drug-free/non-smokers) with informed consent and was approved as per the guide-
lines of Institutional Human Ethical Committee (IHEC-UOM No. 40Res/2013-14), University of Mysore, 
Mysuru. It was immediately mixed with acid-citrate dextrose (ACD) anti-coagulant (2.5% tri-sodium 
citrate, 2% D-glucose, 1.5% citric acid) in the ratio of 7:1 (blood : ACD, v/v). The anti-coagulated blood 
was then centrifuged at 90 × g at 37 °C for 15 min and the supernatant thus obtained was the platelet-rich 
plasma (PRP). The PRP was centrifuged at 700 × g for 15 min at 37 °C. The platelet pellet thus obtained 
was suspended in CGS buffer (123 mM NaCl, 33 mM D-glucose, 13 mM tri-sodium citrate, pH 6.5) and 
washed thereafter at 700 × g for 15 min at 37 °C. The previous washing step was repeated one more time. 
Finally, the washed platelets (WP) were suspended in Tyrode’s buffer (2.5 mM HEPES, 150 mM NaCl, 
2.5 mM KCl, 12 mM NaHCO3, 1 mM CaCl2, 1 mM MgCl2, 5.5 mM D-glucose, pH 7.4)49. The cell count 
was determined in both PRP and WP suspension using a Neubauer chamber and adjusted to 5 × 108 
cells/mL in the final suspension using platelet poor plasma/Tyrode’s buffer.
Recruitment of hyperbilirubinemia (HB) subjects. HB subjects (n = 35) from Government 
Ayurvedic Medical College (GAMC), Mysuru were recruited for the study (Supplementary Table 1). 
HB subjects were recruited purely on basis of serum bilirubin level (reference range: 1.5–15 mg of total 
bilirubin/dL of blood). Cirrhotic, viral and obstructive jaundice patients were excluded from the study. 
All the experiments were in accordance and approved by the Institutional Human Ethical Committee 
(IHEC-UOM No. 47Res/2014-15), University of Mysore, Mysuru. Venous blood was drawn from HB 
subjects and non-smoking/drug-free healthy subjects (HS, n = 21) by trained professionals from GAMC, 
Mysuru. Platelets and serum samples were separated for further analysis. About ⅓ fraction of the drawn 
blood was used to separate serum and the remaining ⅔ fraction was immediately mixed with ACD in the 
ratio of 7:1 (blood: ACD, v/v). About 100 μ L aliquots of anti-coagulated blood was used to determine cell 
count in an automated hemo-analyser (Sysmex KX-21, Japan). Further, the remaining anti-coagulated 
blood was then centrifuged to obtain PRP and WP. The cell count was determined in both PRP and WP 
suspension using a Neubauer chamber and adjusted to 5 × 108 cells/mL in the final suspension using 
platelet poor plasma/Tyrode’s buffer. Serum was stored at − 80 °C until further use.
Phenylhydrazine (PHZ)-induced hyperbilirubinemia. Wistar rats of 4–6 week old were used 
for the experiments. The experimental animals were grouped as: Group I - Saline control; Group II - 
PHZ-induced, and each group consisted of 6 rats. Unconjugated hyperbilirubinemia was induced by 
injecting a single dose of PHZ (75 mg/kg) intraperitoneally and housed for two days50. Thereafter, animals 
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were euthanized and blood was collected immediately through cardiac puncture. About ⅓ fraction of the 
collected blood was used to separate serum and the remaining ⅔ fraction was immediately mixed with 
ACD in the ratio of 5:1 (blood: ACD, v/v). About 100 μ L aliquots of anti-coagulated blood was used to 
determine cell count in an automated hemo-analyser. Further, the remaining anti-coagulated blood was 
then centrifuged to obtain PRP and WP. The cell count was determined in both PRP and WP suspension 
using a Neubauer chamber and adjusted to 5 × 108 cells/mL in the final suspension using platelet poor 
plasma/Tyrode’s buffer. Liver and spleen tissues from experimental animals were harvested and rinsed in 
ice cold saline, serum was separated and stored at − 80 °C for further analysis.
Flow cytometry. WP (1 × 106 cells/mL) were independently treated with UCB (0–200 μ M) and ABT-
737 (1 μ M) as positive control, and incubated for 30 min at 37 °C. After incubation, cells were stained 
using CM-H2DCFDA, JC-1, NAO (10-nonyl acridine orange) and Annexin V-FITC, washed and ana-
lysed using FACSVerseTM flow cytometer (BD Biosciences, USA).
Determination of reactive oxygen species (ROS). Endogenous ROS generation in platelets was 
determined according to the method of Thushara et al.51. WP (5 × 106 cells/mL) were taken separately 
in 96-well plates and treated with A23187 (1 μ M) as positive control or UCB (0–200 μ M) as test and the 
final volume was made up to 200 μ L with Tyrode’s buffer and incubated for 30 min at 37 °C. For inhibition 
studies, pre-loaded platelets with UCB (200 μ M), were incubated with Mito-TEMPO (10 μ M) and incu-
bated for 30 min at 37 °C. The untreated and treated platelets were then incubated with CM-H2DCFDA 
(10 μ M) for 30 min at 37 °C and the fluorescence was recorded using a Varioskan multimode plate reader 
(Thermo Scientific, USA) by exciting the samples at 488 nm and measuring the resulting fluorescence at 
530 nm. The same procedure was followed for untreated WP obtained from HS, HB and experimental 
animals.
Estimation of intracellular calcium. Intracellular Ca2+ concentration was measured in WP accord-
ing to the method of Thushara et al.51. WP (5 × 106 cells/mL) were treated with A23187 (1 μ M) or UCB 
(0–200 μ M) and the final volume was made up to 200 μ L with Tyrode’s buffer containing 1 mM Cacl2 
and incubated for 30 min at 37 °C followed by incubation with fura-2/AM (2 μ M). The fura-2/AM fluo-
rescence was determined by exciting the samples at 340 and 380 nm and the resulting fluorescence was 
measured at 500 nm. Data were presented as absorption ratios (340/380 nm). The same procedure was 
followed for untreated WP obtained from HS, HB and experimental animals.
Determination of changes in mitochondrial membrane potential (ΔΨm). The cationic dye 
JC-1 was used to detect changes in the Δ Ψ m according to the method of Thushara et al.51. WP (5 × 106 
cells/mL) were treated with UCB (0–200 μ M) and the final volume was made up to 200 μ L with Tyrode’s 
buffer and incubated for 30 min at 37 °C. The samples were loaded with JC-1 (2 μ M) at 37 °C for 10 min. 
The cells were then excited at 488 nm and emission was detected at 585 nm for JC-1 aggregates and 516 nm 
for JC-1 monomers using multimode plate reader. Data were presented as emission ratios (585/516). The 
same procedure was followed for untreated WP obtained from HS, HB and experimental animals.
Assessment of cardiolipin peroxidation. 10-Nonyl acridine orange (NAO), a fluorescent probe was 
used to detect peroxidation of cardiolipin. NAO loses its affinity for peroxidised cardiolipin resulting in 
decreased fluorescence. WP (5 × 106 cells/mL) were processed as discussed above with either A23187 
(1 μ M) or UCB (0–200 μ M) and then loaded with NAO (1 μ M) and incubated for 30 min at 37 °C. After 
incubation the fluorescence was recorded by exciting the samples at 499 nm and emission was recorded at 
530 nm52. The same procedure was followed for untreated WP obtained from HS, HB and experimental 
animals.
Assessment of mPTP formation. Formation of mPTP in platelets was assessed using calcein AM53. 
WP (5 × 106 cells/mL) were treated with A23187 (1 μ M), UCB (0–200 μ M) and incubated for 30 min at 
37 °C. Following incubation calcein AM (1 μ M) along with CoCl2 (1 mM) for quenching cytosolic calcein 
fluorescence was added. Fluorescence was recorded by exciting the samples at 488 nm and emission was 
detected at 585 nm. The same procedure was followed for untreated WP obtained from HS and HB.
Determination of PS externalization. PS externalization was determined according to the method 
of Thushara et al.51. WP (5 × 106 cells/mL) were treated with UCB (0–200 μ M) and for inhibition studies, 
pre-loaded platelets with UCB (200 μ M) were incubated with Pifithrin-μ (5 μ M)/z-DEVD-fmk (5 μ M) 
and the final volume was made up to 200 μ L with Tyrode’s buffer and incubated for 30 min at 37 °C. The 
untreated and treated platelets were stained with Annexin V-FITC (0.6 μ g/mL) and fluorescence was 
measured in a multimode plate reader by exciting the samples at 496 nm and emission was recorded at 
516 nm. The same procedure was followed for untreated WP obtained from HS, HB and experimental 
animals.
Subcellular fractionation of platelets. UCB (0–200 μ M) treated WP (1 × 108 cells/mL) were sus-
pended in isolation buffer (225 mM mannitol, 75 mM sucrose, 0.1 mM EGTA, 1 mg/mL fatty acid-free 
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BSA, 10 mM HEPES-KOH, proteinase inhibitor mixture, phosphatase inhibitor mixture, pH 7.4) and 
were frozen in liquid nitrogen for 1 min and then thawed at 37 °C for 3 min. This freeze-and-thaw 
sequence was repeated for two more cycles, and then the samples were centrifuged at 700 × g for 10 min 
at 4 °C. The supernatant was further centrifuged at 15,000 × g for 10 min at 4 °C. The pellet was regarded 
as the mitochondria-rich fraction, and the supernatant was considered as the cytosolic fraction54.
Immunobloting. To determine the expression level of various proteins, WP (1 × 108 cells/mL) 
were treated with UCB (0–200 μ M) and for inhibition studies, UCB (200 μ M) treated platelets were 
pre-incubated with Mito-TEMPO (2 μ M)/SB203580 (2 μ M)/Pifithrin-μ (5 μ M)/z-DEVD-fmk (5 μ M)/ 
BSA (5 mg/mL) and incubated at 37 °C for 30 min. Further, platelet suspensions were lysed by add-
ing 10 μ L lysis buffer (20 mM Tris-HCl, pH 8, containing 0.5% Triton-X 100, 150 mM NaCl along with 
cocktail of protease inhibitors). Following centrifugation, the supernatants were separated on SDS-PAGE 
(4–14%) and proteins were transferred onto PVDF membrane. After blocking, the blots were probed 
with antibodies against phospho-p38 (Thy180/Tyr182), p38, phospho-p53 (ser15), p53, cyt. c, caspase-9, 
caspase-3, Bax, Bcl-2, BAD, phospho BAD, tBid, COX-IV, GAPDH and β -tubulin at 4 °C overnight. Blots 
were then incubated with horseradish-peroxidase (HRP)-conjugated secondary antibody and developed 
by enhanced chemiluminescence method and the bands were visualized using chemiluminescence imag-
ing system (Alliance 2.7, Uvitec, UK). For re-probing, blots were incubated in stripping buffer (200 mM 
glycine, pH-2.2, 1% Tween-20 and 0.1% SDS) for 2 min and washed with TBST. Blots were again treated 
with stripping buffer for 5 min and washed thrice with TBST, 2 min each wash. The stripped membrane 
was blocked in TBST containing 5% non-fat milk powder over night at 4 °C and probed with desired 
antibodies54. The same procedure was followed for untreated WP obtained from HS, HB and experi-
mental animals.
Electron transport chain (ETC) assays. Assays for ETC complexes I, II, III and IV were performed 
as described previously55. Briefly, platelet mitochondria were isolated as described above and were treated 
with UCB (0–200 μ M) along with vehicle control (DMSO). Complex I activity (NADH: ubiquinone 
oxidoreductase) was measured by the oxidation of NADH and the activity was expressed as mM NADH 
oxidised/min/mg protein. Complex II activity (succinate: ubiquinone oxidoreductase) was determined 
by the reduction of dichlorophenolindophenol (DCIP) and the activity was expressed as mM DCIP 
reduced/min/mg protein. Complex III activity (coenzyme Q: cytochrome c-oxidoreductase) was meas-
ured by cyt. c reduction and the activity was expressed as mM cyt. c reduced/min/mg protein. Complex 
IV (cyt. c oxidase) activity was measured by the oxidation of cyt. c and the activity was expressed as 
first-order rate constant (k) of mM cyt. c oxidized/min/mg protein.
Evaluation of lysosomal acidity. For monitoring the changes in pH of lysosomes, pH sensitive dye 
LysoSensor Green DND-189 (LSG) was used56. LSG accumulates in intact lysosomes and its fluorescence 
decreases upon lysosome alkalinisation. WP (5 × 106 cells/mL) were independently treated with UCB 
(0–200 μ M) or A23187 (1 μ M) and incubated for 30 min at 37 °C. Further untreated and treated samples 
were loaded with LSG (1 μ M) and incubated for 30 min at 37 °C. Fluorescence was recorded by exciting 
the samples at 488 nm and emission at 510 nm. The same procedure was followed for untreated WP 
obtained from HS and HB.
Estimation of glucose-6-phosphate dehydrogenase (G6PDH) enzyme activity. G6PDH 
activity was determined in WP treated with either A23187 (1 μ M) or UCB (0–200 μ M) and incubated 
for 30 min at 37 °C. After incubation, platelets were pelleted, suspended in distilled water and lysed by 
sonication. Activity was monitored by adding platelet lysate (50 μ g) to 1 mL reaction volume (50 mM 
Tris-HCl, pH 7.5 containing 3.8 mM NADP, 3.3 mM glucose-6-phosphate and 6.3 mM MgCl2). Increase 
in absorbance was recorded at 340 nm for 3 min due to NADP+-dependent glucose 6-phosphate trans-
formation and the activity was expressed as mM NADPH formed/min/mg protein57.
Measurement of γ-Glutamyltransferase (GGT) activity. To determine the GGT activity, WP 
(5 × 106 cells/mL) were treated with either A23187 (1 μ M) or UCB (0–200 μ M) and incubated for 30 min 
at 37 °C. After incubation, platelets were pelleted, suspended in distilled water and lysed by sonication. 
The resulting lysate was used to determine GGT activity according to the method of Sener et al.16. 
Activity was monitored in 1 mL reaction volume consisting of γ -glutamyl-p-nitroanilide (4 mM), glycylg-
lycine (40 mM) in Tris-HCl buffer (185 mM, pH 8.2). The results were calculated using molar extinction 
coefficient for p-nitroanilide (9,900 M−1cm−1) at 405 nm expressed as mM p-nitroanilide formed/min/mg 
protein. The same procedure was followed for untreated WP obtained from HS and HB.
Measurement of LDH leakage. WP (5 × 106 cells/mL) were treated either with UCB (0–200 μ M) 
or with A23187 (1μ M) for 30 min at 37 °C and platelets were pelleted by centrifugation at 3,700 × g for 
10 min. Supernatants were used to detect LDH release by using LDH kit, according to the manufactur-
er’s protocol. The assay was performed in a time course of decrease in NADH absorbance at 340 nm for 
3 min.
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Evaluation of platelets viability by MTT assay. MTT colorimetric assay was performed to assess 
the cell viability58. WP (1 × 106 cells/mL) was taken separately in 96-well microtiter plates and treated 
with either A23187 (1 μ M) or with UCB (0–200 μ M) and the final volume was made up to 200 μ L with 
Tyrode’s buffer. After 30 min of incubation, 250 μ M of MTT was added and incubated for additional 3 h. 
Thereafter, MTT was removed and remaining formazan crystals were completely dissolved in DMSO and 
the absorbance was recorded at 570 nm.
Platelet aggregation assay. Platelet aggregation was determined by turbidimetric method with 
a dual channel Chrono-log model 700-2 aggregometer (Havertown, USA). Briefly, 250 μ L of WP 
(1.5 × 108 cells/mL) was taken in siliconized glass cuvette and pre-incubated for 5 min at 37 °C with UCB 
(0–200 μ M), and the aggregation was initiated by the addition of collagen (2 μ g/mL). The aggregation was 
then followed with constant stirring at 1200 rpm for 6 min at 37 °C59.
Platelet adhesion assay. Platelet adhesion assay was performed according to the method by Kumar 
et al.60. Briefly, 20 μ g of collagen type I in 200 μ L PBS was added independently to 96-well polystyrene 
microtiter plates and kept for 16 h at 4 °C. The coated wells were then blocked by adding 200 μ L of 1% 
BSA in PBS for 1 h at 37 °C and washed with PBS. In the first set of experiment, UCB (0–200 μ M) was 
directly added to the collagen type I coated wells, incubated for 10 min followed by washing with PBS 
and then WP (1.5 × 108 cells/mL) was added. In the second set of experiment, WP pre-treated with UCB 
(0–200 μ M) for 10 min at 37 °C was added to the pre-coated collagen type I wells. The total reaction vol-
ume was made up to 200 μ L with PBS. The reaction mixture was incubated at 37 °C for 90 min and then 
washed with PBS. The adherent platelets were then lysed by adding 150 μ L lysis buffer (100 mM citrate 
buffer pH 5.4 containing 5 mM p-nitrophenyl phosphate and 0.1% Triton X-100) at 37 °C for 90 min. 
The reaction was terminated by inactivating the membrane bound acid phosphatase with the addition of 
100 μ L stopping reagent (2 N NaOH). The colour developed was measured at 405 nm. Platelet adhesion 
was expressed as percent adhesion, considering PBS-treated platelet suspension as 100%.
Macrophage engulfment assay. Engulfment of apoptotic platelets from monocyte derived mac-
rophage was assessed as described by Kumari et al.61. In brief, blood drawn from healthy donors 
(drug-free/non-smokers) was collected in citrate containing tube, and peripheral blood mononuclear 
cells (PBMCs) were isolated using Histopaque-1077 according to the standard protocol from the man-
ufacturer. The obtained PBMCs were plated onto polystyrene culture flasks for 4 h at 37 °C and washed 
with PBS to remove non-adherent lymphocytes. Monocytes (200,000 in 500 μ L volume) were then plated 
on to 6-well plates in RPMI 1640 medium supplemented with 10% fetal bovine serum and cultured for 
7 days to obtain monocyte-derived macrophages. Control and UCB (200 μ M) - treated platelets labelled 
with calcein-AM were incubated with adherent monolayer of monocyte-derived macrophages for 45 min. 
Following the incubation period, the phagocyte monolayer was washed to remove non-interacting plate-
lets, and adherent macrophages were removed by treatment with trypsin at 37 °C for 5 min, followed by 
5 mM EDTA at 4 °C. Monocyte-derived macrophages were recovered by trypsin-EDTA treatment for 
15 min at 37 °C and subjected to flow cytometric analysis.
Histological assessment of liver and spleen tissues. The liver and spleen tissues were dissected 
out and blotted free of blood, rinsed in ice-cold saline and fixed in 10% buffered formalin for overnight. 
The tissue samples were subjected to dehydration by processing with different grades of alcohol and 
chloroform mixture. The processed tissues were embedded in paraffin wax, and sections (5 μ m thick-
ness) were prepared, stained with hematoxylin- eosin dye (H&E) and observed under an Axio imager.
A2 microscope (Oberkochen, Germany) and photographed.
Protein estimation. The protein estimation was done according to the method of Lowry et al.62 using 
BSA as standard.
Statistical analysis: All the results were expressed as mean ± SEM of five independent experi-
ments. Statistical significance among groups was determined by t-test and one way analysis of variance 
(ANOVA) followed by Tukey’s test for comparison of means as appropriate.
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